Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Income towards Parent Company: 2019-2024

Historic Income towards Parent Company for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to -$86.6 million.

  • Foghorn Therapeutics' Income towards Parent Company rose 13.87% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.0 million, marking a year-over-year increase of 17.80%. This contributed to the annual value of -$86.6 million for FY2024, which is 11.99% up from last year.
  • Foghorn Therapeutics' Income towards Parent Company amounted to -$86.6 million in FY2024, which was up 11.99% from -$98.4 million recorded in FY2023.
  • Over the past 5 years, Foghorn Therapeutics' Income towards Parent Company peaked at -$69.5 million during FY2020, and registered a low of -$108.9 million during FY2022.
  • Over the past 3 years, Foghorn Therapeutics' median Income towards Parent Company value was -$98.4 million (recorded in 2023), while the average stood at -$98.0 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' Income towards Parent Company crashed by 47.58% in 2021, and later climbed by 11.99% in 2024.
  • Foghorn Therapeutics' Income towards Parent Company (Yearly) stood at -$69.5 million in 2020, then plummeted by 47.58% to -$102.6 million in 2021, then fell by 6.14% to -$108.9 million in 2022, then rose by 9.60% to -$98.4 million in 2023, then increased by 11.99% to -$86.6 million in 2024.